← Home

RESEARCH BY INDUSTRY

Evidence for the decision.

Find published research and synthetic demonstrations, with planned and developing topics clearly separated.

9 published public-data studies4 synthetic demonstrations51 planned or developing topics

Pharmaceuticals and biotechnology

0 published studies · 3 planned or developing topics

Planned topics & work in progress

No findings are published for this selection yet. These topics are separate from completed findings. Each status reflects the work actually performed.

S19 / Pharmaceuticals and biotechnology

Compound selection when laboratory tests are expensive

A discovery team must choose which compounds to test next under a limited assay budget. Evaluate whether uncertainty-aware selection finds active compounds more efficiently than random screening or choosing the largest predicted activity.

Planned topic

Proposed design & source

Molecular representations; uncertainty estimation; active learning

Choose a well-populated ChEMBL target and a compatible endpoint. Harmonize units, assay types and duplicate compound measurements before defining the label. Compare molecular-fingerprint models with one graph-based challenger. Run retrospective active-learning rounds by revealing withheld assay labels only after a selection.

Evaluation: Use scaffold-separated and, when feasible, publication-time holdouts. Compare random, greedy and uncertainty/diversity acquisition under identical label budgets. Report hit rate, enrichment, calibration and chemical diversity; repeat acquisition trials with multiple seeds.

Boundary: This is retrospective selection within a measured compound pool. It does not establish clinical efficacy, safety, prospective laboratory hit rates or discovery of a new drug.

ChEMBL ↗

S20 / Pharmaceuticals and biotechnology

Trial completion risk from information available at registration

A clinical-development operations team must anticipate prolonged or unsuccessful trial execution. Study whether registration-time design and enrollment characteristics predict completion timing and early termination.

Planned topic

Proposed design & source

Competing risks; survival calibration; historical snapshot design

Define a cohort by registration period and study type. Reconstruct fields as recorded at registration using accessible record history or dated snapshots; do not use later actual enrollment or revised completion dates as baseline predictors. Fit competing-event models for completion and termination, retaining ongoing trials as censored.

Evaluation: Use later registration cohorts as holdouts, allowing adequate follow-up. Compare simple phase/design strata with regularized survival models. Report horizon-specific calibration, censoring-adjusted Brier scores, event counts and sensitivity to status-reporting lag.

Boundary: Current registry records alone cannot support a leakage-free registration-time forecast. If history cannot be recovered, deliver a retrospective association study and label it accordingly; registry completion is not scientific success.

ClinicalTrials.gov study records ↗

S21 / Pharmaceuticals and biotechnology

Does molecular data add stable prognostic information?

A translational research team must decide whether a complex molecular signature adds information beyond a simpler clinical baseline. Test this increment under rigorous leakage and batch-effect controls in one cancer cohort.

Planned topic

Proposed design & source

Penalized Cox models; pathway aggregation; multi-omic integration

Select only open TCGA clinical and processed molecular files with usable outcome definitions. Start with a clinical Cox model, add a prespecified pathway-level representation and compare with penalized multi-omic survival modeling. Perform normalization and feature selection inside training folds and keep all samples from a patient together.

Evaluation: Use nested patient-level validation and a collection-site holdout if feasible. Report time-specific calibration, concordance, integrated Brier score and feature stability. Test proportional-hazards assumptions and clinical-variable missingness; identify external validation as a future requirement.

Boundary: Retrospective prognostic association does not identify treatment benefit. Open TCGA cohorts do not establish clinical utility or readiness for patient care; controlled-access files are outside this project's scope.

TCGA open-access data through GDC ↗

The 60-topic program spans 20 industries, with 9 studies published. Synthetic demonstrations are counted separately. Unpublished topics have no public case-study route.

Privacy preferences

Security verification and inquiry delivery are essential. These optional choices do not affect them.

Optional services may remain unavailable until configured. No raw chat, search or contact text belongs in analytics. Read the privacy notice.